This is a preprint.
Assessing long-term pleiotropic effects of potential novel triglyceride-lowering medications using variants identified by Mendelian randomization
- PMID: 40963757
- PMCID: PMC12440046
- DOI: 10.1101/2025.03.07.25323588
Assessing long-term pleiotropic effects of potential novel triglyceride-lowering medications using variants identified by Mendelian randomization
Abstract
Drugs targeting triglyceride (TG)-associated genes have the potential to improve cardiovascular outcomes. However, we know little regarding the potential additional benefits or deleterious effects of such targeting. As such, in ancestry-specific cohorts of European ancestry (EA) and African ancestry (AA) at Vanderbilt (BioVU), we used PheWAS to test associations between measured TG levels and validated variants previously associated with TG levels in Mendelian randomization studies. We replicated results in All of Us (AoU). In the BioVU EA cohort (n=63,094), 9 of 10 validated SNPs had significant or suggestive associations with lipid and cardiovascular phenotypes, largely consistent with AoU participants of EA (n=97,545). In the BioVU AA cohort (n=12,515) and AoU AA cohort (n=31,710), results were more limited; only 1 of 6 validated SNPs was significantly associated with a lipid or cardiovascular phenotype in either BioVU or AoU, and no significant or suggestive associations were consistent across both cohorts. We detected few secondary effects in either EA or AA BioVU patients, and none were replicated. These results suggest that there may be limited additional benefits, but few deleterious effects, associated with targeting known TG-associated genes. However, these targets may not be as effective for mitigating cardiovascular risk among individuals of AA.
Keywords: Triglycerides; drug side effects; mendelian randomization; phewas.
Conflict of interest statement
Drs. Mundo and Zhong reported receiving support from National Institutes of Health (NIH) grants during the conduct of the study. Ms. Karakoc reported receiving support from the Vanderbilt Physician Scientist Development Award during the conduct of the study. Dr. Cox reported receiving an honorarium from the Endocrine Society during the conduct of the study. Dr. Stein reported receiving support from NIH grants, book royalties, and an honorarium for writing a textbook chapter during the conduct of the study. The remaining authors declared no competing interests for this work.
Figures
References
-
- The top 10 causes of death. https://test-cms.who.int/news-room/fact-sheets/detail/the-top-10-causes-... (2025).
-
- Miller M. et al. Triglycerides and Cardiovascular Disease A Scientific Statement From the American Heart Association. Circulation 123, 2292–2333 (2011). - PubMed
-
- Hokanson J. E. & Austin M. A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3, 213–219 (1996). - PubMed
-
- Nichols G. A., Philip S., Reynolds K., Granowitz C. B. & Fazio S. Increased Cardiovascular Risk in Hypertriglyceridemic Patients With Statin-Controlled LDL Cholesterol. The Journal of Clinical Endocrinology & Metabolism 103, 3019–3027 (2018). - PubMed
Publication types
Grants and funding
- UL1 TR000445/TR/NCATS NIH HHS/United States
- R01 HL163854/HL/NHLBI NIH HHS/United States
- OT2 OD026556/OD/NIH HHS/United States
- R01 GM120523/GM/NIGMS NIH HHS/United States
- U2C OD023196/OD/NIH HHS/United States
- U19 HL065962/HL/NHLBI NIH HHS/United States
- OT2 OD025315/OD/NIH HHS/United States
- U24 OD023121/OD/NIH HHS/United States
- OT2 OD026552/OD/NIH HHS/United States
- OT2 OD026549/OD/NIH HHS/United States
- OT2 OD025337/OD/NIH HHS/United States
- OT2 OD025277/OD/NIH HHS/United States
- OT2 OD025276/OD/NIH HHS/United States
- UL1 RR024975/RR/NCRR NIH HHS/United States
- OT2 OD026554/OD/NIH HHS/United States
- U24 OD023163/OD/NIH HHS/United States
- OT2 OD023206/OD/NIH HHS/United States
- R01 HL171809/HL/NHLBI NIH HHS/United States
- U24 OD023176/OD/NIH HHS/United States
- OT2 OD026548/OD/NIH HHS/United States
- S10 RR025141/RR/NCRR NIH HHS/United States
- OT2 OD026551/OD/NIH HHS/United States
- P30 EY008126/EY/NEI NIH HHS/United States
- OT2 OD026555/OD/NIH HHS/United States
- R01 HL133786/HL/NHLBI NIH HHS/United States
- OT2 OD026550/OD/NIH HHS/United States
- OT2 OD026553/OD/NIH HHS/United States
- P50 GM115305/GM/NIGMS NIH HHS/United States
- OT2 OD023205/OD/NIH HHS/United States
- P30 CA068485/CA/NCI NIH HHS/United States
- OT2 OD026557/OD/NIH HHS/United States
- UL1 TR002243/TR/NCATS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous